Curevo is a clinical-stage biotechnology company focused on developing vaccines with improved tolerability and accessibility. Its lead product, amezosvatein, is a non-mRNA adjuvanted sub-unit vaccine designed to prevent shingles. The company raised $110M in a Series B to accelerate clinical development. Curevo intends to use the funds to extend its Phase 2 program by an additional 640 participants, including adults over age 70, to finalize dose selection ahead of Phase 3. Leadership includes CEO George Simeon, and the financing is accompanied by additions to the board to support late-stage development planning. The company is based in Seattle, WA. Curevo Vaccine is a Seattle-based, clinical-stage biotech focused on developing safe, highly effective subunit vaccines using an adjuvanted platform. Its lead candidate, CRV-101, is an adjuvanted subunit vaccine being evaluated to prevent shingles in older adults and was designed to use a smaller amount of adjuvant to aim for comparable efficacy with fewer side effects. In Phase 1, CRV-101 showed robust humoral and cellular immunogenicity with no grade 3 injection-site reactions and a 1.3% rate of grade 3 systemic side effects. CRV-101 is in a head-to-head Phase 2b trial versus Shingrix®, in which Curevo enrolled 678 patients in six months; topline data were expected in early 2023. The company is also developing a non-live subunit chickenpox vaccine. Financially, Curevo completed a $26 million Series A1 financing and previously raised $86 million in 2022, which company management says extends its cash runway. Curevo Vaccine is a clinical-stage biotech based in Seattle focused on developing safe, highly effective adjuvanted subunit vaccines via its sub-unit vaccine technology platform. Its lead product, CRV-101, is an adjuvanted sub-unit vaccine under investigation to prevent shingles in older adults and is designed to use less adjuvant to aim for similar efficacy with fewer side effects. The company reported encouraging Phase 1 data showing robust humoral and cellular immunogenicity, no grade 3 injection-site side effects, and a 1.3% rate of grade 3 systemic side effects. Curevo is conducting a 678-patient Phase 2b trial intended to compare CRV-101’s immunogenicity and safety profile relative to Shingrix. The firm is also developing a non-live subunit chickenpox vaccine to address unmet needs for more accessible vaccines. Curevo announced a $60 million Series A to fund clinical development through topline data from the Phase 2b trial.

Total raised

$196M

Funding rounds

3

Latest round

Series B

Latest activity

Mar 2025